It took a team of researchers more than 18 months to get their paper on epigenetic variation published—likely because they are saying that epigeneticists have been fishing in the wrong pond for a decade.
Throughout Jim Allison’s early career, the field of oncology appeared to be unfazed by his T cell research. Allison’s introduction to the now-famed immune cell came in an undergraduate immunology course, where even the professor was apprehensive about Allison’s fascination with the recently discovered T cells. “I remember going to see the professor after class […]
Medicare Advantage, the private insurance alternative to traditional Medicare, is popular for several reasons: lower premiums, dental and vision coverage, and a cap on out-of-pocket costs.
Some job relocations are less cumbersome than others. When Jedd Wolchok left Memorial Sloan Kettering Cancer Center after more than a quarter century, he crossed East 68th Street to Weill Cornell campus, where he is now the director of the Sandra and Edward Meyer Cancer Center.
When Kay Dickersin was diagnosed with breast cancer in 1986, the support group available to her in Baltimore focused largely on how to get the makeup and wig to look right.
Ruben A. Mesa is going into the new year with a massive new challenge: bring together the programs and cultures of an academic cancer center and a hybrid cancer center—and convincing NCI that the new organization should keep its elite designation.
Monica Bertagnolli, the 16th director of the National Cancer Institute, announced that she will be undergoing treatment for early-stage breast cancer.
The past six weeks have brought fundamental change in the way oncology drugs are being developed. At this unprecedented moment in oncopolitics, FDA, NCI, academic oncologists, advocates, and the industry are in agreement on how cancer therapies should be developed, tested and approved.
Pragmatica-Lung is the first of what is likely to be a series of simpler trials with relaxed enrollment criteria and streamlined data collection requirements.
The Pragmatica-Lung trial required many people to start to think differently about conducting phase III clinical trials—and it took a lot of advocacy to make the trial launch quickly, said Ellen Sigal, founder and chair of Friends of Cancer Research.
